Anaemia
Conditions
Interventions
Total Hip Arthroplasty Control group:For definitive diagnosis of ID, IDE, IDA, iron sucrose injection (200 mg intravenous infusion three times a week) + human erythropoietin (3000 IU subcutaneous inje
Artificial femoral head replacement control group:For definitive diagnosis of ID, IDE, IDA, iron sucrose injection (200 mg intravenous infusion three times a week) + human erythropoietin (3000 IU subc
Total hip arthroplasty experimental group:For a definitive diagnosis of ID, IDE, IDA, ferric carboxymaltose injection (1000 mg intravenous infusion once a week) + human erythropoietin (3000 IU subcuta
Artificial femoral head replacement experimental group:For a definitive diagnosis of ID, IDE, IDA, ferric carboxymaltose injection (1000 mg intravenous infusion once a week) + human erythropoietin (30
Sponsors
Panzhihua Central Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age= 65 years; 2. There are no other systemic diseases or other diseases that have been controlled and managed, and there is no obvious obstacle to daily diet, activity, sleep and other general conditions. 3. Before the operation, the anteroposterior pelvic X-ray, the anterolateral femur on the affected side, and the hip CT scan were completed, and it was confirmed that the patient had a femoral neck/femoral intertrochanteric fracture and chose to undergo hip replacement. 4. Patients and their families agree to the iron deficiency assessment monitoring and red blood cell mobilization program, be informed about the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with multiple fractures; 2. Preoperative respiratory, circulatory, urinary, digestive and other systemic diseases, which have an impact on the patient's daily life; 3. Limb paralysis, severe deformity or musculoskeletal system disease that seriously affects the patient's postoperative recovery before admission; 4. Abnormal coagulation function due to illness or medication before injury; 5. Combined with primary hematologic diseases; 6. Allergy to tranexamic acid, iron sucrose, and carboxyl iron; 7. Patients who terminate the study due to changes in their condition or other factors and lack of clinical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| haemoglobin;Hematocrit;Red blood cell volume;Serum iron;Transferrin saturation;ferritin;Harris score; | — |
Countries
China
Contacts
Public ContactXunzhou Song
Panzhihua Central Hospital
Outcome results
None listed